Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers

Rhumbline Advisers reduced its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,955 shares of the company’s stock after selling 909 shares during the period. Rhumbline Advisers owned about 0.08% of Kiniksa Pharmaceuticals worth $1,166,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in KNSA. Braidwell LP increased its stake in Kiniksa Pharmaceuticals by 40.6% during the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock valued at $72,334,000 after purchasing an additional 836,210 shares during the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after buying an additional 108,102 shares during the last quarter. FMR LLC raised its stake in Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after acquiring an additional 694,928 shares during the period. Jane Street Group LLC lifted its holdings in Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after acquiring an additional 315,456 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Kiniksa Pharmaceuticals by 40.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock worth $8,098,000 after acquiring an additional 92,985 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 54.57% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Stock Up 0.3 %

KNSA stock opened at $21.39 on Thursday. The stock has a market cap of $1.54 billion, a PE ratio of -152.77 and a beta of 0.48. The firm’s 50-day simple moving average is $19.70 and its 200 day simple moving average is $22.41. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter last year, the company posted $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.